Promising stem cell therapy against progressive multiple sclerosis

Promising stem cell therapy against progressive multiple sclerosis

An international team have tried an injection with mother cells in the brain of patients with multiple sclerosis progressive (MS) and has shown that the therapy is safe, well tolerated and protects the brain from further damage.

Directed by the University of Cambridge, University of Milan Bicocca and Casa Sollievo della Sofferenza Hospital (Italy)the study is a step toward developing a cell therapy treatment for progressive MS.

In the world, more than two million people have MS and, although some treatments reduce the severity and frequency of relapses, about 25 or 30 years after diagnosis, 65% of patients move to a secondary phase of the disease in which the disability constantly worsens.

In MS, one’s own immune system of the body attacks and damages myelin, the protective sheath that surrounds nerve fiberswhich causes the interruption of messages sent through the brain and spinal cord.

The key immune cells involved in this process are macrophages that normally attack and eliminate unwanted intruders from the body. In this case, it affects a particular type of macrophage known as a microglial cell that is found throughout the brain and spinal cord.

In progressive forms of MS, they attack the central nervous system (CNS), causing chronic inflammation and damage to nerve cells.

The latest studies have led us to think that stem cell therapies could help alleviate this damage.

Previous work by the Cambridge team has shown in mice that skin cells reprogrammed into brain stem cells, transplanted into the central nervous system, can help reduce inflammation and contribute to repairing the damage caused by multiple sclerosis.

Now, in research published this past Monday in Cell Stem Cell, the team has completed for the first time an early-stage human clinical trial that consisted of injecting neural stem cells into the brains of 15 patients with secondary MS recruited at two hospitals in Italy.

The stem cells were obtained from cells taken from brain tissue of a single donor fetus who suffered a miscarriage.

No deaths or serious adverse events

The team followed the patients for 12 months, during which time there were no deaths or serious adverse events, only some temporary or reversible side effects.

All patients had high levels of disability at the beginning of the trial – most needed a wheelchair, for example – but during the 12-month follow-up none of them worsened.

None of the patients had symptoms suggesting a relapse nor did their cognitive function significantly worsen during the study. For researchers, all this indicates substantial stability of the disease, with no signs of progression.

The researchers evaluated changes in brain tissue volume associated with disease progression in a subgroup of patients and found that the higher the dose of stem cells injected, the smaller the reduction in brain volume over time.

The team believes this may be because the stem cell transplant dampened inflammation. They also looked for evidence that stem cells protected nerve cells from further damage.

Their previous work showed that modifying metabolism – the way the body produces energy – can reprogram microglia from “bad” to “good.”

In the new study, they analyzed how brain metabolism changes after treatment. To do this, they measured changes in the fluid surrounding the brain and in the blood over time and found certain signs related to the way the brain processes fatty acids.

These signs were related to the effectiveness of the treatment and the evolution of the disease. and the higher the dose of stem cells, the higher the fatty acid levels, which also persisted over the 12-month period.

After the trial, Stefano Pluchino, co-director of the study and researcher at the University of Cambridge, was “cautiously enthusiastic” about the findings “which represent a step towards the development of a cell therapy to treat MS.”

And although he recognizes that The study has limitations (it is small and there may have been confounding effects due to immunosuppressive drugs, for example), That the treatment is safe and its effects last 12 months “means that we can move on to the next phase of clinical trials.”

Kumneger Media
Kumneger Media
Kumneger Media is a News and Entertainment Website & Channel. Kumneger Media in addition to News and Entertainment it is the hub of Politics, Movies, Drama, Music, Comedy, Documentary and More!